Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27085902 | 0.86 | MEN1 (0.53) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL15847583 | 0.81 | MAPT (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16541886 | 0.81 | CA2 (0.53) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL28712446 | 0.81 | SMN1; SMN2 (0.59) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| Bromide SCHEMBL16180801 | 0.79 | CA2 (0.52) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL31090163 | 0.79 | SMN1; SMN2 (0.61) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL16233087 | 0.79 | SMN1; SMN2 (0.61) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL13403262 | 0.78 | KDM1A (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL8297975 | 0.77 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL2144460 | 0.77 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | claimed |
| EP-1497255-A2 | METHOD FOR PREPARING COMBRETASTATINS | Aventis Pharma S.A. (FR) | 2005-01-19 | — | — | EP | claimed |
| US-6759555-B2 | CONDENSING (3,4,5-TRIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE WITH 3-NITRO-4-METHOXYBENZALDEHYDE, REDUCING THE NITRO INTERMEDIATE TO FORM 2-METHOXY-5-(2-(3,4,5-TRIMETHOXYPHENYL)-ETHENYL)ANILINE | AVENTIS PHARMA S.A. (FR) | 2004-07-06 | — | — | US | claimed |
| US-20030220404-A1 | Process for the preparation of combretastatins | AVENTIS PHARMA S.A. (FR) | 2003-11-27 | — | — | US | claimed |
| WO-2003084919-A2 | METHOD FOR PREPARING COMBRETASTATINS | AVENTIS PHARMA S.A. (FR) | 2003-10-16 | — | — | WO | claimed |
| EP-2354118-A1 | Process for the preparation of combretastatine | Aventis Pharma S.A. (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354118-A1 | Process for the preparation of combretastatine | Aventis Pharma S.A. (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| EP-1497255-A2 | METHOD FOR PREPARING COMBRETASTATINS | Aventis Pharma S.A. (FR) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003084919-A2 | METHOD FOR PREPARING COMBRETASTATINS | AVENTIS PHARMA S.A. (FR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220404-A1 | Process for the preparation of combretastatins | TGFB2, HMGCR, TGFB1 | MEN1 487/4885KMT2A 969/4885ALDH1A1 2753/4885 |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | MEN1 3474/4885KMT2A 4266/4885ALDH1A1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.